| 1.09 0.08 (7.92%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.65 | 1-year : | 2.25 |
| Resists | First : | 1.41 | Second : | 1.92 |
| Pivot price | 1.2 |
|||
| Supports | First : | 0.57 | Second : | 0.48 |
| MAs | MA(5) : | 1.06 |
MA(20) : | 1.24 |
| MA(100) : | 0.8 |
MA(250) : | 1.8 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 14.1 |
D(3) : | 10.4 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 3.29 | Low : | 0.49 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ XLO ] has closed above bottom band by 26.5%. Bollinger Bands are 10.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.11 - 1.12 | 1.12 - 1.12 |
| Low: | 1.03 - 1.03 | 1.03 - 1.04 |
| Close: | 1.08 - 1.09 | 1.09 - 1.1 |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Tue, 16 Apr 2024
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why - Yahoo Finance
Wed, 03 Apr 2024
Gilead Sciences acquires $368,790 in Xilio Therapeutics stock By Investing.com - Investing.com
Mon, 01 Apr 2024
Xilio Therapeutics Inc (XLO) Up 37.96% in Premarket Trading - InvestorsObserver
Mon, 01 Apr 2024
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results - Yahoo Finance
Thu, 28 Mar 2024
Xilio stock jumps on Gilead Sciences license deal (NASDAQ:GILD) - Seeking Alpha
Thu, 28 Mar 2024
Why Is Cancer Focused Xilio Therapeutics Stock Trading Higher On Thursday? - Xilio Therapeutics (NASDAQ:X - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 37 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 31.8 (%) |
| Held by Institutions | 49.3 (%) |
| Shares Short | 54 (K) |
| Shares Short P.Month | 21 (K) |
| EPS | -2.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.33 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -49.5 % |
| Return on Equity (ttm) | -107.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -69 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -0.4 |
| PEG Ratio | 0 |
| Price to Book value | 0.81 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|